Newsmakers: IndiGo profit at record high, new iPhones launched and more

IndiGo profit at record high: The country's largest airline by market share reported Rs 1,304 crore ($196 million) in net profit in the year to the end of March, two sources familiar with the matter said on Thursday, up from Rs 317 crore a year earlier. IndiGo 's parent company InterGlobe Aviation is preparing to list on the stock exchange after filing a draft prospectus in June as it looks to cash in on the airline's success.

Firms with Brazil exposure slide on bourses: Shares of Indian companies with exposure to Brazil witnessed selling pressure on Thursday after Standard & Poor's (S&P) downgraded the Latin American country to junk status. Companies with exports to Brazil saw heavy selling, led by Torrent Pharma, which settled for the day with losses of 4.83 per cent.

iPhone 6s, 6s Plus launched: With the launch of the new iPhones, the older generations get a price cut. As Apple has announced the iPhone 6S and iPhone 6S Plus, the prices of the unlocked iPhone 6 and 6 Plus have also dropped in the international market. The iPhone 6 16GB will be available for $549 and the 64GB variant for $649. The iPhone 6Plus 16GB's new price is $649 and $749 for the 64GB variant. But, this doesn't seem to bring any changes in the pricing of the iPhone 6 and 6 Plus models in India as they are not retailing at the MRP but at a much lower price.

M&M launches TUV300: Mahindra & Mahindra, multinational automobile manufacturing firm, launched compact SUV TUV300 at an introductory price starting at Rs 6.9 lakh (ex-showroom Pune), as it aims to strengthen its market share in the utility vehicles segment. TUV300, which comes only with a diesel engine, is priced up to Rs 9.12 lakh for the top-end variant which showcases the AMT (auto gear shift) technology.

Sun Pharma looking to divest Ireland plant: India's largest drugmaker by sales, said it is looking to divest a manufacturing plant in Ireland as it tries to control costs that have spiralled since it bought Ranbaxy Laboratories. The world's fifth largest generic drugmaker has been working on resolving issues at Ranbaxy's India-based drug manufacturing sites, all of which have been banned from exporting to its largest market, the United States, over quality control issues.